King's College London, London, UK.
Oral Dis. 2021 Nov;27(8):1993-2007. doi: 10.1111/odi.13797. Epub 2021 Feb 26.
The ability to predict malignant transformation in oral potentially malignant disorders would inform targeted treatment, provide prognostic information and allow secondary prevention. DNA ploidy and loss of heterozygosity assays are already in clinical use, and loss of heterozygosity has been used in prospective clinical trials. This review appraises published evidence of predictive ability and explores interpretation of heterogeneous studies, with different diagnostic methods, criteria and intention. Both methods have a sound biological foundation and have predictive value independent of dysplasia grading and clinical parameters. The application of these two techniques cannot be directly compared because of differences in expression of results and application to populations of different risk. Predicting malignant transformation accurately on an individual patient basis is not yet possible with either technique. However, they are valuable applications to stratify patients for inclusion in trials, identify the lowest risk patients and exclude risk when biopsy results are indeterminate for dysplasia.
预测口腔潜在恶性疾病恶性转化的能力将有助于针对性治疗、提供预后信息和进行二级预防。DNA 倍体和杂合性丢失检测已经在临床中使用，并且杂合性丢失已用于前瞻性临床试验。本综述评估了已发表的预测能力的证据，并探讨了不同诊断方法、标准和目的的异质研究的解释。这两种方法都有坚实的生物学基础，并且具有独立于异型增生分级和临床参数的预测价值。由于结果表达和应用于不同风险人群的差异，这两种技术的应用不能直接进行比较。然而，这两种技术对于分层患者以纳入试验、确定风险最低的患者以及在活检结果不确定为异型增生时排除风险是非常有价值的应用。
